<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Robot Surg</journal-id><journal-id journal-id-type="iso-abbrev">J Robot Surg</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>Journal of Robotic Surgery</journal-title></journal-title-group><issn pub-type="ppub">1863-2483</issn><issn pub-type="epub">1863-2491</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12474697</article-id><article-id pub-id-type="pmcid-ver">PMC12474697.1</article-id><article-id pub-id-type="pmcaid">12474697</article-id><article-id pub-id-type="pmcaiid">12474697</article-id><article-id pub-id-type="pmid">41003879</article-id><article-id pub-id-type="doi">10.1007/s11701-025-02829-w</article-id><article-id pub-id-type="publisher-id">2829</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Evaluation of the analgesic efficacy of dinalbuphine sebacate in transoral robotic surgery for obstructive sleep apnea&#8211;hypopnea syndrome: a single-center retrospective cohort study</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0009-0009-9341-6139</contrib-id><name name-style="western"><surname>Li</surname><given-names initials="CW">Cheng-Wei</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0009-0001-8379-6344</contrib-id><name name-style="western"><surname>Hsu</surname><given-names initials="YH">Yueh-Hsien</given-names></name><address><email>hyh3977@hotmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-7934-9437</contrib-id><name name-style="western"><surname>Tsao</surname><given-names initials="CH">Chien-Han</given-names></name><address><email>Q1203738@gmail.com</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01abtsn51</institution-id><institution-id institution-id-type="GRID">grid.411645.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0638 9256</institution-id><institution>Department of Anesthesiology, </institution><institution>Chung Shan Medical University Hospital, </institution></institution-wrap>Taichung City, 40201 Taiwan </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01abtsn51</institution-id><institution-id institution-id-type="GRID">grid.411645.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0638 9256</institution-id><institution>Department of Otolaryngology, </institution><institution>Chung Shan Medical University Hospital, </institution></institution-wrap>No. 110, Sec. 1, Jianguo N. Rd., South District, Taichung City, 40201 Taiwan </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/059ryjv25</institution-id><institution-id institution-id-type="GRID">grid.411641.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 0532 2041</institution-id><institution>School of Medicine, </institution><institution>Chung Shan Medical University, </institution></institution-wrap>Taichung City, 40201 Taiwan </aff></contrib-group><pub-date pub-type="epub"><day>26</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>19</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">497685</issue-id><elocation-id>636</elocation-id><history><date date-type="received"><day>20</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>18</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>26</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>28</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-28 14:25:15.427"><day>28</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="11701_2025_Article_2829.pdf"/><abstract id="Abs1"><p id="Par1">Obstructive sleep apnea&#8211;hypopnea syndrome (OSAHS) is a chronic disorder with significant comorbidities. Transoral robotic surgery (TORS) combined with uvulopalatopharyngoplasty (UPPP) is an established treatment, but postoperative pain management remains challenging. This study evaluates the efficacy of dinalbuphine sebacate (DNS), an extended-release analgesic, in reducing opioid use and managing postoperative pain in TORS UPPP patients. This retrospective cohort included consecutive TORS-UPPP patients from 1 January 2020 to 30 June 2024; the database was locked on 30 June 2024 prior to analysis. The patients were divided into a DNS group (<italic toggle="yes">n</italic>&#8201;=&#8201;96) and a conventional analgesia (CA) group (<italic toggle="yes">n</italic>&#8201;=&#8201;42). The DNS group received a 150&#160;mg intramuscular injection after anesthetic induction and after the surgery. Analgesic consumption, opioid usage, and pain scores were evaluated from the day of surgery (POD0) to two days postoperatively (POD2), as well as opioid prescriptions at discharge and during the first follow-up. The DNS group exhibited a significantly lower percentage of opioid use during POD0&#8211;POD2 (30.21% vs. 54.76%, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) and a reduced oral morphine equivalent dose (15.31&#8201;&#177;&#8201;36.68&#160;mg vs. 56.79&#8201;&#177;&#8201;85.83&#160;mg, <italic toggle="yes">p</italic>&#8201;=&#8201;0.001). Opioid prescriptions at discharge (68.75% vs. 88.10%, <italic toggle="yes">p</italic>&#8201;=&#8201;0.016) and at the first follow-up (13.54% vs. 52.38%, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) were also lower in the DNS group, with comparable analgesic effects. DNS effectively reduces postoperative opioid consumption and prescription in TORS UPPP patients without significant adverse effects. These findings support the integration of DNS into multimodal analgesia protocols for OSAHS surgery, substantially reduced inpatient and post-discharge opioid use (NNT &#8776; 3&#8211;5) with small, likely non-clinically important differences in pain scores and no significant safety signal, supporting its clinical relevance in OSAHS surgical programs. Warranting further multicenter validation.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s11701-025-02829-w.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Dinalbuphine sebacate</kwd><kwd>Transoral robotic surgery</kwd><kwd>Uvulopalatopharyngoplasty</kwd><kwd>Postoperative analgesia</kwd><kwd>Opioid</kwd></kwd-group><funding-group><award-group><funding-source><institution>department of medical research, Chung Shan Medical University Hospital</institution></funding-source><award-id>CSH-2025-A-010</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer-Verlag London Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Obstructive sleep apnea&#8211;hypopnea syndrome (OSAHS) is a chronic airway-related disorder linked to significant comorbidities individually, including cardiovascular disease, metabolic syndrome, and neuropsychiatric dysfunction. Beyond the personal outcomes, OSAHS imposes a substantial and heterogeneous burden globally, with high prevalence across regions and far&#8209;reaching health and socioeconomic consequences; recent syntheses highlight underdiagnosis, elevated accident risk, and increased healthcare utilization, underscoring OSA as a public&#8209;health priority [<xref ref-type="bibr" rid="CR1">1</xref>]. In the United States alone, undiagnosed OSA was estimated to cost&#8201;~&#8201;$149.6&#160;billion (2015), with productivity losses accounting for the largest share, alongside motor-vehicle and workplace accidents and higher healthcare utilization; treatment is associated with improved attendance and on-the-job productivity [<xref ref-type="bibr" rid="CR2">2</xref>].Among OSAHS patients with surgically correctable upper-airway anatomical abnormalities, interventions including tonsillectomy, uvulopalatopharyngoplasty (UPPP), and radiofrequency for base of tongue (RFBOT) are considered with effective therapeutic options before when applied to carefully selected cases [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par3">Transoral robotic surgery (TORS) combined with UPPP&#8212;approved by the U.S. Food and Drug Administration (FDA) in 2009 for the treatment of OSAHS&#8212;represents an advanced surgical technique designed to reduce tongue base volume and expand the oropharyngeal and hypopharyngeal airways. This approach, often performed with supraglottoplasty, has been shown to significantly improve the apnea&#8211;hypopnea index (AHI) and Epworth sleepiness scale (ESS), with reductions averaging 58% in previous studies [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par4">Despite its proven efficacy, TORS is frequently associated with severe postoperative pain and dysphagia, which can hinder recovery and adversely affect patient comfort. Postoperative pain may last up to three weeks [<xref ref-type="bibr" rid="CR6">6</xref>]. Severe cases may result in complications such as dehydration, with uncontrolled pain or dehydration necessitating readmission in 3.3&#8211;9.6% of patients undergoing TORS [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. These findings highlight the critical importance of effective postoperative pain management in this population.</p><p id="Par5">Opioids are commonly used for postoperative pain control; however, their use in OSAHS patients presents unique challenges due to a high incidence of opioid-induced respiratory depression (47.0&#8211;84.3%), particularly in opioid-na&#239;ve or sleep-disordered individuals [<xref ref-type="bibr" rid="CR9">9</xref>]. This predisposition increases the risk of postoperative pulmonary complications. Moreover, patients undergoing OSAHS surgery are at risk of excessive opioid prescribing, which can lead to prolonged or inappropriate opioid use, especially among opioid-na&#239;ve individuals who receive perioperative opioid prescriptions [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. Recognizing these risks, the American Society of Anesthesiologists (ASA) has recommended minimizing or eliminating systemic opioid use in the perioperative management of OSA patients in 2018 [<xref ref-type="bibr" rid="CR12">12</xref>]. Similarly, in 2021, the American Academy of Otolaryngology-Head and Neck Surgery (AAOHNS) emphasized prioritizing non-opioid analgesics for postoperative pain management in otolaryngologic surgeries. The AAOHNS also recommended evaluating patients for opioid misuse risk factors preoperatively [<xref ref-type="bibr" rid="CR13">13</xref>]. These guidelines underscore the growing consensus among anesthesiologists and otolaryngologists to reduce opioid use in the postoperative care of patients undergoing UPPP.</p><p id="Par6">Dinalbuphine sebacate (DNS, Naldebain&#174;) is an extended-release formulation and prodrug of nalbuphine developed for a single-dose intramuscular injection. After injection into the gluteus maximus, DNS is gradually released into the plasma and rapidly converted into nalbuphine, with a mean absorption time of 145.2&#160;h [<xref ref-type="bibr" rid="CR14">14</xref>]. This prolonged release provides a long-lasting analgesic effect, rendering DNS a promising option for postoperative pain management since its approval by the Taiwan FDA in 2017. Clinical studies have demonstrated its efficacy in reducing the score relative to the pain numeric rating scale (NRS) and opioid consumption [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Additionally, the Taiwan Society of Anesthesiologists&#8217; expert consensus supports incorporating DNS into multimodal analgesia (MMA) strategies to optimize postoperative pain control [<xref ref-type="bibr" rid="CR17">17</xref>]. Effective pain management strategies that combine analgesics with different pharmacological mechanisms during the perioperative and inpatient periods can significantly reduce postoperative pain and opioid consumption in TORS patients [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>].</p><p id="Par7">At our institution, TORS UPPP with the Da Vinci system has been employed for the treatment of OSAHS since 2016. DNS has been integrated into MMA strategies for this patient population since 2020. This study aims to retrospectively evaluate whether the perioperative and inpatient use of DNS in TORS UPPP for OSAHS patients can reduce postoperative opioid consumption and requirement, effectively alleviate postoperative pain, and decrease postoperative complications. By addressing these objectives, this study seeks to contribute to the development of safer and more effective pain management protocols for OSAHS patients undergoing TORS UPPP.</p><p id="Par8">Patients with OSA/OSAHS are vulnerable to opioid-related ventilatory impairment, and major perioperative guidelines recommend multimodal, opioid-sparing strategies with careful dosing and postoperative monitoring. These include the American Society of Anesthesiologists (ASA) practice guideline for perioperative management of OSA and the Society of Anesthesia and Sleep Medicine (SASM) intraoperative guideline, which collectively advocate preferential non-opioid analgesics, minimization of systemic opioids, and risk-adapted surveillance [<xref ref-type="bibr" rid="CR20">20</xref>]. In otolaryngology, the AAO-HNSF opioid prescribing guideline likewise emphasizes multimodal analgesia and judicious opioid use across common procedures [<xref ref-type="bibr" rid="CR21">21</xref>]. Within TORS programs, enhanced-recovery protocols have demonstrated reductions in postoperative opioid consumption and pain scores, reinforcing the value of opioid stewardship in this setting [<xref ref-type="bibr" rid="CR19">19</xref>]. This framework provides the rationale to evaluate whether a DNS-anchored multimodal regimen can reduce inpatient opioid requirements and opioid prescribing after TORS-UPPP.</p></sec><sec id="Sec2"><title>Materials and methods</title><p id="Par9">This retrospective, single-center, comparative cohort study was designed to evaluate the clinical efficacy of DNS compared to conventional analgesic strategies in postoperative pain management following UPPP. The study adhered to the principles of the Declaration of Helsinki and was approved by the Institutional Review Board of the affiliated hospital (IRB number: CS1-24,073). The study content and format comply with the combined STROBE checklist [<xref ref-type="bibr" rid="CR22">22</xref>]. We retrospectively analyzed patients diagnosed with OSAHS who underwent TORS UPPP using the Da Vinci system (Intuitive Surgical, Sunnyvale, CA, USA) at our center from 1 January 2020 to 30 June 2024. Data were censored at 30 June 2024 (database lock), and analyses were performed thereafter; the study was approved by the IRB (CS1-24,073, waiver of consent).</p><p id="Par10">The inclusion of these dates was based on the introduction of DNS into the otolaryngology department of our hospital in January 2020. Patients were eligible for inclusion if they had a confirmed diagnosis of OSAHS and a documented record of undergoing TORS UPPP. The exclusion criteria were as follows: (1) preoperative diagnosis of substance abuse, defined as the excessive use of illicit drugs or prescription pain medication; (2) documented history of psychiatric disorders, including depression or anxiety; (3) chronic pain disorder; and (4) diagnosis of dementia. The intervention group was defined as patients who received a complete two-dose regimen of DNS; therefore, patients who only received a single dose were also excluded. A total of 138 patients were included; 96 patients were categorized in the DNS group, and 42 patients were included in the conventional analgesia (CA) group. The patient inclusion and exclusion flowchart is detailed in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>Flow diagram of this study</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="11701_2025_2829_Fig1_HTML.jpg"/></fig></p><sec id="Sec3"><title>Procedures</title><p id="Par11">All patients underwent general anesthesia with endotracheal intubation, which was maintained with volatile anesthetics. Two otolaryngologists performed all surgical procedures. Patients were divided into two groups based on the use of DNS. Patients in the DNS group received a single 150&#160;mg intramuscular injection of DNS immediately after anesthetic induction, followed by a second 150&#160;mg injection 5&#8211;7&#160;days postoperatively. Both injections were guided via ultrasound and administered into the gluteus maximus in order to ensure accuracy and safety. The patients in the CA group did not receive DNS during or after surgery; instead, they were managed with other standard analgesic strategies as determined by the anesthesiologist. After surgery, all patients were monitored in the post-anesthesia care unit (PACU) for 1&#8211;2&#160;h and received appropriate analgesics as determined by the anesthesiologist. Patients were transferred to the ward when their Aldrete score reached&#8201;&#8805;&#8201;9.</p><p id="Par12">Postoperatively, patients experiencing pain in the ward were managed with analgesics other than DNS based on the physician&#8217;s discretion and the patient&#8217;s preference. Pain intensity was assessed immediately upon return to the ward and subsequently at fixed times (05:00, 13:00, and 21:00) by the ward primary care nurse using a standard numeric rating scale (NRS, 0&#8211;10); In this study, postoperative pain was assessed using the Numeric Rating Scale (NRS), ranging from 0 to 10, where 0 indicated no pain and 10 represented the worst imaginable pain. Pain assessment was considered the &#8220;fifth vital sign&#8221; and was recorded by nursing staff together with routine vital signs after the patient returned to the ward. Standard assessment time points included immediately upon return to the ward and at 05:00, 13:00, and 21:00 each day. The assessment was conducted verbally by the nurse, asking: &#8220;If 10 represents the worst possible pain and 0 represents no pain, what is your current pain score?&#8221; The patient&#8217;s response was directly documented in the nursing records. These results were recorded in the electronic medical record (EMR). Pain assessments did not differentiate between swallowing pain and resting pain. Patients reporting nausea or vomiting during hospitalization were treated with parenteral prochlorperazine or metoclopramide depending on the situation. Following adequate pain control and wound evaluation, patients were prescribed oral analgesics and discharged. Patients were educated to seek emergency care if they experienced postoperative discomfort.</p></sec><sec id="Sec4"><title>Data collection</title><p id="Par13">All data were obtained from the hospital&#8217;s EMR system, which includes anesthesia records, surgical records, inpatient care records, and outpatient follow-up records. The system undergoes regular internal review and incorporates error correction mechanisms to ensure data completeness and accuracy. Demographic characteristics, including age, gender, height, weight, body mass index (BMI), ASA classification, and surgical time, were recorded. The types and dosages of analgesics administered intraoperatively in the PACU, during the inpatient period, and during outpatient follow-up were thoroughly analyzed based on EMR data.</p><p id="Par14">Analgesic and antiemetic types and dosages administered intraoperatively, on the day of surgery, and during the first two postoperative days were retrieved from the EMR and analyzed in detail. Opioid medications were converted to oral morphine equivalent (OME) doses following the conversion tables provided by the European Society of Anaesthesiology and Intensive Care [<xref ref-type="bibr" rid="CR23">23</xref>] (see Supplementary Materials S1). Discharge prescriptions were examined to determine whether opioids were prescribed. Opioid use was defined as the prescription of morphine, tramadol, or other opioid analgesics recorded in the EMR. Outpatient follow-up records were reviewed for postoperative opioid prescriptions.</p><p id="Par15">Pain intensity was assessed on the ward using an 11-point NRS at fixed time points and recorded as part of routine vital signs during the period of in-hospital. While outpatient NRS at the first clinic follow-up is not documented in a standardized fashion in our EMR; therefore, so we used opioid prescribing at that visit as a consistent post-discharge outcome.</p><p id="Par16">For patients readmitted to the emergency department (ED), detailed records were reviewed to determine the reason for admission. Pain-related readmissions were defined as cases where analgesics were administered in the ER. Bleeding-related readmissions were defined as cases requiring hemostatic intervention, and dizziness-related readmissions were defined as cases requiring antiemetic administration.
</p><p>Perioperative analgesic pathway and agents by phase for DNS vs conventional analgesia (CA). The flow diagram of figure <xref rid="Fig2" ref-type="fig">2</xref>&#160;displays standardized phases&#8212;Counseling/Allocation, Induction, Intraoperative, PACU, Inpatient (POD0&#8211;2), and Discharge/1st Follow&#8209;up&#8212;for the DNS and conventional analgesia (CA) cohorts. The DNS cohort received 150&#160;mg IM at induction with a scheduled second 150&#160;mg IM on POD5&#8211;7, within a multimodal regimen. Both cohorts received perioperative non&#8209;opioid agents with rescue short&#8209;acting opioids as needed. This figure corresponds to the Dosage section; quantitative details (consumption/OME, outcomes) appear in Merged Table&#160;<xref rid="Tab1" ref-type="table">1</xref> and Table&#160;<xref rid="Tab4" ref-type="table">4</xref></p><fig id="Fig2" position="float" orientation="portrait"><label>Fig.&#160;2</label><caption><p>Perioperative analgesic pathway and agents by phase for DNS vs conventional analgesia (CA)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="11701_2025_2829_Fig2_HTML.jpg"/></fig></sec><sec id="Sec5"><title>Study endpoints</title><p id="Par17">Primary endpoints included the proportion of patients requiring opioids for pain management in the general ward on the day of surgery (POD 0) and the first two postoperative days (POD1 and POD2); OME doses; and the proportion of patients prescribed opioids upon discharge and during the first outpatient follow-up. Secondary endpoints included intraoperative OME doses, PACU OME doses, NRS scores on POD 0&#8211;2, the proportion of patients receiving antiemetics during hospitalization, ER readmission rates, and rehospitalization rates.</p></sec><sec id="Sec6"><title>Statistical analysis</title><p id="Par18">Continuous variables are presented as mean&#8201;&#177;&#8201;standard deviation, and categorical variables are presented as numbers (percentages). Statistical analyses were performed using SAS (SAS &#174; Enterprise Guide &#174; 8.4 version). Continuous variables, such as OME doses, were tested for normality using the Shapiro&#8211;Wilk test. Data following a normal distribution were analyzed using an independent <italic toggle="yes">t</italic>-test, while non-normally distributed data were analyzed using the Mann&#8211;Whitney U test. Categorical variables, such as the proportion of patients requiring opioids within three postoperative days, were analyzed using chi-square or Fisher&#8217;s exact tests, depending on the expected values in the contingency table. Missing NRS data were handled using mean imputation. For potential confounding factors, multivariable logistic regression models were employed to assess the true effect of DNS and control for confounding factors. A <italic toggle="yes">p</italic>-value&#8201;&lt;&#8201;0.05 was considered statistically significant.</p></sec></sec><sec id="Sec7"><title>Results</title><sec id="Sec8"><title>Patient characteristics</title><p id="Par19">A total of 138 patients were included, with 96 in the DNS group and 42 in the CA group (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). The mean age was 40.81&#160;years old, with no significant difference between the DNS and CA groups (39.81&#8201;&#177;&#8201;9.70 vs. 43.10&#8201;&#177;&#8201;12.40; <italic toggle="yes">p</italic>&#8201;=&#8201;0.133). Similarly, the mean BMI was 28.73, with no significant difference between the DNS group (29.09&#8201;&#177;&#8201;5.56) and the CA group (27.91&#8201;&#177;&#8201;5.91; <italic toggle="yes">p</italic>&#8201;=&#8201;0.113). The mean surgical time was 90.76&#160;min; the DNS group had significantly shorter surgical times (84.88&#8201;&#177;&#8201;17.72) than the CA group (104.21&#8201;&#177;&#8201;41.44; <italic toggle="yes">p</italic>&#8201;=&#8201;0.040). The sex distribution (male: 82.3% vs. 64.3%, <italic toggle="yes">p</italic>&#8201;=&#8201;0.021) was male-dominant in the DNS group, and the ASA classification was comparable between the groups.
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>Patient characteristics and demographics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">DNS group (<italic toggle="yes">n</italic>&#8201;=&#8201;96)</th><th align="left" colspan="1" rowspan="1">CA group (<italic toggle="yes">n</italic>&#8201;=&#8201;42)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age (years old)</td><td align="left" colspan="1" rowspan="1">39.81&#8201;&#177;&#8201;9.7</td><td align="left" colspan="1" rowspan="1">43.10&#8201;&#177;&#8201;12.4</td><td char="." align="char" colspan="1" rowspan="1">0.13</td></tr><tr><td align="left" colspan="1" rowspan="1">Gender</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">0.02</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Male</td><td align="left" colspan="1" rowspan="1">79 (82.3%)</td><td align="left" colspan="1" rowspan="1">27 (64.3%)</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Female</td><td align="left" colspan="1" rowspan="1">17 (17.7%)</td><td align="left" colspan="1" rowspan="1">15 (35.7%)</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Height (cm)</td><td align="left" colspan="1" rowspan="1">170.11&#8201;&#177;&#8201;7.13</td><td align="left" colspan="1" rowspan="1">166.50&#8201;&#177;&#8201;7.97</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Weight (kg)</td><td align="left" colspan="1" rowspan="1">84.36&#8201;&#177;&#8201;17.86</td><td align="left" colspan="1" rowspan="1">77.38&#8201;&#177;&#8201;16.56</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Body mass index</td><td align="left" colspan="1" rowspan="1">29.09&#8201;&#177;&#8201;5.56</td><td align="left" colspan="1" rowspan="1">27.91&#8201;&#177;&#8201;5.91</td><td char="." align="char" colspan="1" rowspan="1">0.11</td></tr><tr><td align="left" colspan="1" rowspan="1">ASA classification</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">0.17</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;I</td><td align="left" colspan="1" rowspan="1">14 (14.6%)</td><td align="left" colspan="1" rowspan="1">2 (4.8%)</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;II</td><td align="left" colspan="1" rowspan="1">69 (71.9%)</td><td align="left" colspan="1" rowspan="1">36 (85.7%)</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;III</td><td align="left" colspan="1" rowspan="1">13 (13.5%)</td><td align="left" colspan="1" rowspan="1">4 (9.5%)</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Surgical time (min)</td><td align="left" colspan="1" rowspan="1">84.88&#8201;&#177;&#8201;17.72</td><td align="left" colspan="1" rowspan="1">104.21&#8201;&#177;&#8201;41.44</td><td char="." align="char" colspan="1" rowspan="1">0.04</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec9"><title>Primary outcomes</title><sec id="Sec10"><title>Postoperative analgesic consumption between the DNS and CA groups</title><p id="Par20">Postoperative analgesic usage relative to POD 0, POD 1, and POD 2 is summarized in Table&#160;<xref rid="Tab2" ref-type="table">2</xref>. The use of parenteral tramadol was higher in the CA group (161.90&#8201;&#177;&#8201;296.28&#160;mg) than in the DNS group (51.04&#8201;&#177;&#8201;122.25&#160;mg; <italic toggle="yes">p</italic>&#8201;=&#8201;0.412). Similarly, oral tramadol consumption was significantly higher in the CA group (82.14&#8201;&#177;&#8201;140.61&#160;mg vs. 0.00&#8201;&#177;&#8201;0.00&#160;mg; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). Regarding non-opioid analgesics, the CA group consumed significantly more acetylsalicylate (773.81&#8201;&#177;&#8201;1668.22&#160;mg vs. 281.25&#8201;&#177;&#8201;1048.34&#160;mg; <italic toggle="yes">p</italic>&#8201;=&#8201;0.005), acetaminophen (711.90&#8201;&#177;&#8201;1218.66&#160;mg vs. 0.00&#8201;&#177;&#8201;0.00&#160;mg; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), and celecoxib (61.90&#8201;&#177;&#8201;227.34&#160;mg vs. 0.00&#8201;&#177;&#8201;0.00&#160;mg; <italic toggle="yes">p</italic>&#8201;=&#8201;0.009). In contrast, parecoxib consumption was significantly higher in the DNS group (137.92&#8201;&#177;&#8201;67.65&#160;mg) than in the CA group (78.10&#8201;&#177;&#8201;86.09&#160;mg; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), necessitating post hoc analysis to evaluate its potential confounding effect on the observed outcomes. Opioid usage differed significantly between the groups, with 30.21% of the DNS group using opioids postoperatively compared to 54.76% in the CA group (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). Additionally, the OME doses were significantly lower in the DNS group (15.31&#8201;&#177;&#8201;36.68&#160;mg vs. 56.79&#8201;&#177;&#8201;85.83&#160;mg; <italic toggle="yes">p</italic>&#8201;=&#8201;0.001).
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table&#160;2</label><caption><p>Postoperative analgesic consumption from the operation day to postoperative day 2</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Phase/outcome</th><th align="left" colspan="1" rowspan="1">DNS (<italic toggle="yes">n</italic>&#8201;=&#8201;96)</th><th align="left" colspan="1" rowspan="1">CA (<italic toggle="yes">n</italic>&#8201;=&#8201;42)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Intraoperative &#8212; OME (mg)</td><td align="left" colspan="1" rowspan="1">40.74&#8201;&#177;&#8201;11.61</td><td align="left" colspan="1" rowspan="1">40.10&#8201;&#177;&#8201;11.36</td><td char="." align="char" colspan="1" rowspan="1">0.75</td></tr><tr><td align="left" colspan="1" rowspan="1">Intraoperative &#8212; Fentanyl (mcg)</td><td align="left" colspan="1" rowspan="1">176.82&#8201;&#177;&#8201;61.37</td><td align="left" colspan="1" rowspan="1">161.90&#8201;&#177;&#8201;47.57</td><td char="." align="char" colspan="1" rowspan="1">0.24</td></tr><tr><td align="left" colspan="1" rowspan="1">Intraoperative &#8212; Morphine (mg)</td><td align="left" colspan="1" rowspan="1">1.79&#8201;&#177;&#8201;2.79</td><td align="left" colspan="1" rowspan="1">2.57&#8201;&#177;&#8201;3.25</td><td char="." align="char" colspan="1" rowspan="1">0.21</td></tr><tr><td align="left" colspan="1" rowspan="1">Intraoperative &#8212; Parecoxib (mg)</td><td align="left" colspan="1" rowspan="1">30.88&#8201;&#177;&#8201;16.83</td><td align="left" colspan="1" rowspan="1">25.71&#8201;&#177;&#8201;19.40</td><td char="." align="char" colspan="1" rowspan="1">0.11</td></tr><tr><td align="left" colspan="1" rowspan="1">Intraoperative &#8212; Ketorolac (mg)</td><td align="left" colspan="1" rowspan="1">0.62&#8201;&#177;&#8201;4.31</td><td align="left" colspan="1" rowspan="1">2.86&#8201;&#177;&#8201;8.91</td><td char="." align="char" colspan="1" rowspan="1">0.05</td></tr><tr><td align="left" colspan="1" rowspan="1">Intraoperative &#8212; Propacetamol (mg)</td><td align="left" colspan="1" rowspan="1">62.50&#8201;&#177;&#8201;349.81</td><td align="left" colspan="1" rowspan="1">47.62&#8201;&#177;&#8201;308.61</td><td char="." align="char" colspan="1" rowspan="1">0.82</td></tr><tr><td align="left" colspan="1" rowspan="1">Intraoperative &#8212; Volatile agent: Desflurane</td><td align="left" colspan="1" rowspan="1">90 (93.75%)</td><td align="left" colspan="1" rowspan="1">35 (83.33%)</td><td char="." align="char" colspan="1" rowspan="1">0.05*</td></tr><tr><td align="left" colspan="1" rowspan="1">Intraoperative &#8212; Volatile agent: Sevoflurane</td><td align="left" colspan="1" rowspan="1">5 (5.21%)</td><td align="left" colspan="1" rowspan="1">7 (16.67%)</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">PACU &#8212; OME (mg)</td><td align="left" colspan="1" rowspan="1">3.13&#8201;&#177;&#8201;5.99</td><td align="left" colspan="1" rowspan="1">1.31&#8201;&#177;&#8201;4.29</td><td char="." align="char" colspan="1" rowspan="1">0.04</td></tr><tr><td align="left" colspan="1" rowspan="1">PACU &#8212; Opioid usage (yes)</td><td align="left" colspan="1" rowspan="1">24 (25.0%)</td><td align="left" colspan="1" rowspan="1">4 (9.5%)</td><td char="." align="char" colspan="1" rowspan="1">0.06</td></tr><tr><td align="left" colspan="1" rowspan="1">PACU &#8212; Fentanyl (mcg)</td><td align="left" colspan="1" rowspan="1">14.06&#8201;&#177;&#8201;28.75</td><td align="left" colspan="1" rowspan="1">6.54&#8201;&#177;&#8201;21.42</td><td char="." align="char" colspan="1" rowspan="1">0.08</td></tr><tr><td align="left" colspan="1" rowspan="1">PACU &#8212; Morphine (mg)</td><td align="left" colspan="1" rowspan="1">0.05&#8201;&#177;&#8201;0.51</td><td align="left" colspan="1" rowspan="1">0.00&#8201;&#177;&#8201;0.00</td><td char="." align="char" colspan="1" rowspan="1">0.52</td></tr><tr><td align="left" colspan="1" rowspan="1">PACU &#8212; Nalbuphine (mg)</td><td align="left" colspan="1" rowspan="1">1.04&#8201;&#177;&#8201;3.32</td><td align="left" colspan="1" rowspan="1">0.60&#8201;&#177;&#8201;1.98</td><td char="." align="char" colspan="1" rowspan="1">0.80</td></tr><tr><td align="left" colspan="1" rowspan="1">PACU &#8212; Ketorolac (mg)</td><td align="left" colspan="1" rowspan="1">0.63&#8201;&#177;&#8201;4.30</td><td align="left" colspan="1" rowspan="1">2.86&#8201;&#177;&#8201;8.91</td><td char="." align="char" colspan="1" rowspan="1">0.05</td></tr><tr><td align="left" colspan="1" rowspan="1">PACU &#8212; Parenteral tramadol (mg)</td><td align="left" colspan="1" rowspan="1">0.52&#8201;&#177;&#8201;5.10</td><td align="left" colspan="1" rowspan="1">0.00&#8201;&#177;&#8201;0.00</td><td char="." align="char" colspan="1" rowspan="1">0.52</td></tr><tr><td align="left" colspan="1" rowspan="1">Inpatient (POD0&#8211;2) &#8212; OME (mg)</td><td align="left" colspan="1" rowspan="1">15.31&#8201;&#177;&#8201;36.68</td><td align="left" colspan="1" rowspan="1">56.79&#8201;&#177;&#8201;85.83</td><td char="." align="char" colspan="1" rowspan="1">0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Inpatient (POD0&#8211;2) &#8212; Opioid usage (yes)</td><td align="left" colspan="1" rowspan="1">29 (30.21%)</td><td align="left" colspan="1" rowspan="1">23 (54.76%)</td><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Inpatient (POD0&#8211;2) &#8212; Parenteral tramadol (mg)</td><td align="left" colspan="1" rowspan="1">51.04&#8201;&#177;&#8201;122.25</td><td align="left" colspan="1" rowspan="1">161.90&#8201;&#177;&#8201;296.28</td><td char="." align="char" colspan="1" rowspan="1">0.42</td></tr><tr><td align="left" colspan="1" rowspan="1">Inpatient (POD0&#8211;2) &#8212; Oral tramadol (mg)</td><td align="left" colspan="1" rowspan="1">0.00&#8201;&#177;&#8201;0.00</td><td align="left" colspan="1" rowspan="1">82.14&#8201;&#177;&#8201;140.61</td><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Inpatient (POD0&#8211;2) &#8212; Nalbuphine (mg)</td><td align="left" colspan="1" rowspan="1">0.31&#8201;&#177;&#8201;3.06</td><td align="left" colspan="1" rowspan="1">0.00&#8201;&#177;&#8201;0.00</td><td char="." align="char" colspan="1" rowspan="1">0.52</td></tr><tr><td align="left" colspan="1" rowspan="1">Inpatient (POD0&#8211;2) &#8212; Parecoxib (mg)</td><td align="left" colspan="1" rowspan="1">137.92&#8201;&#177;&#8201;67.65</td><td align="left" colspan="1" rowspan="1">78.10&#8201;&#177;&#8201;86.09</td><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Inpatient (POD0&#8211;2) &#8212; Ketorolac (mg)</td><td align="left" colspan="1" rowspan="1">0.00&#8201;&#177;&#8201;0.00</td><td align="left" colspan="1" rowspan="1">5.00&#8201;&#177;&#8201;32.40</td><td char="." align="char" colspan="1" rowspan="1">0.14</td></tr><tr><td align="left" colspan="1" rowspan="1">Inpatient (POD0&#8211;2) &#8212; Acetylsalicylate (mg)</td><td align="left" colspan="1" rowspan="1">281.25&#8201;&#177;&#8201;1048.34</td><td align="left" colspan="1" rowspan="1">773.81&#8201;&#177;&#8201;1668.22</td><td char="." align="char" colspan="1" rowspan="1">0.005</td></tr><tr><td align="left" colspan="1" rowspan="1">Inpatient (POD0&#8211;2) &#8212; Oral acetaminophen (mg)</td><td align="left" colspan="1" rowspan="1">0.00&#8201;&#177;&#8201;0.00</td><td align="left" colspan="1" rowspan="1">711.90&#8201;&#177;&#8201;1218.66</td><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Inpatient (POD0&#8211;2) &#8212; Oral celecoxib (mg)</td><td align="left" colspan="1" rowspan="1">0.00&#8201;&#177;&#8201;0.00</td><td align="left" colspan="1" rowspan="1">61.90&#8201;&#177;&#8201;227.34</td><td char="." align="char" colspan="1" rowspan="1">0.009</td></tr></tbody></table><table-wrap-foot><p>OME values are expressed as mg oral morphine equivalents (means&#8201;&#177;&#8201;SD unless otherwise specified)</p><p>Conversion factors are provided in Supplementary Table <xref rid="MOESM1" ref-type="media">S1</xref></p><p>Phase definitions: intraoperative (induction to emergence), PACU (immediate postoperative care), inpatient POD0&#8211;2 (ward)</p><p>One patient in the DNS group lacked volatile-agent data and was excluded from that specific comparison</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec11"><title>Opioid prescription between the DNS and the CA group</title><p id="Par21">Table <xref rid="Tab3" ref-type="table">3</xref> compares opioid prescription rates between the DNS and CA groups at discharge and during the first outpatient follow-up. At discharge, opioid prescriptions were lower in the DNS group (68.75%) than in the CA group (88.10%; <italic toggle="yes">p</italic>&#8201;=&#8201;0.016). During the first outpatient follow-up, the difference increased, with only 13.54% of the DNS group pre-scribed opioids compared to 52.38% relative to the CA group (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001).
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table&#160;3</label><caption><p>Opioid prescription conditions</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Phase/outcome</th><th align="left" colspan="1" rowspan="1">DNS (<italic toggle="yes">n</italic>&#8201;=&#8201;96)</th><th align="left" colspan="1" rowspan="1">CA (<italic toggle="yes">n</italic>&#8201;=&#8201;42)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Inpatient opioid prescription (any)</td><td align="left" colspan="1" rowspan="1">29 (30.21%)</td><td align="left" colspan="1" rowspan="1">23 (54.76%)</td><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Opioid prescription at discharge (any)</td><td align="left" colspan="1" rowspan="1">66 (68.75%)</td><td align="left" colspan="1" rowspan="1">37 (88.10%)</td><td char="." align="char" colspan="1" rowspan="1">0.016</td></tr><tr><td align="left" colspan="1" rowspan="1">Opioid prescription at first outpatient follow&#8209;up (any)</td><td align="left" colspan="1" rowspan="1">13 (13.54%)</td><td align="left" colspan="1" rowspan="1">22 (52.38%)</td><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="Sec12"><title>Secondary outcomes</title><sec id="Sec13"><title>Intraoperative and PACU analgesia between the DNS and CA groups</title><p id="Par22">The consumption of intraoperative analgesics (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>) was analyzed between the two groups. No statistically significant differences were observed in intraoperative opioid and adjunct analgesic consumption. The DNS group demonstrated an average OME dose of 40.74&#8201;&#177;&#8201;11.61&#160;mg, which was comparable to the CA group&#8217;s 40.10&#8201;&#177;&#8201;11.36&#160;mg (<italic toggle="yes">p</italic>&#8201;=&#8201;0.754). In the PACU (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>), a smaller proportion of patients in the CA group required opioids (9.5%) than in the DNS group (25.0%), but this difference did not reach statistical significance (<italic toggle="yes">p</italic>&#8201;=&#8201;0.064). The mean OME doses in the PACU were significantly higher in the DNS group than in the CA group (3.13&#8201;&#177;&#8201;5.99 vs. 1.31&#8201;&#177;&#8201;4.29&#160;mg; <italic toggle="yes">p</italic>&#8201;=&#8201;0.044).</p></sec><sec id="Sec14"><title>Postoperative pain NRS between the DNS and CA groups</title><p id="Par23">Table <xref rid="Tab4" ref-type="table">4</xref> summarizes the NRS pain scores from POD0 to POD2. The mean NRS when patients returned to the ward showed no significant difference between the DNS (2.38&#8201;&#177;&#8201;1.52) and CA groups (2.52&#8201;&#177;&#8201;1.74; <italic toggle="yes">p</italic>&#8201;=&#8201;0.753). On POD 1, the mean NRS was significantly higher in the DNS group (1.73&#8201;&#177;&#8201;0.73) than in the CA group (1.41&#8201;&#177;&#8201;0.76; <italic toggle="yes">p</italic>&#8201;=&#8201;0.025). By POD 2, the mean NRS in the DNS group was also significantly higher than in the CA group (1.62&#8201;&#177;&#8201;0.71 vs. 1.34&#8201;&#177;&#8201;0.79; <italic toggle="yes">p</italic>&#8201;=&#8201;0.031).
<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table&#160;4</label><caption><p>Intraoperative analgesic consumption</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Phase/outcome</th><th align="left" colspan="1" rowspan="1">DNS (<italic toggle="yes">n</italic>&#8201;=&#8201;96)</th><th align="left" colspan="1" rowspan="1">CA (<italic toggle="yes">n</italic>&#8201;=&#8201;42)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">NRS &#8212; when returned to ward</td><td align="left" colspan="1" rowspan="1">2.38&#8201;&#177;&#8201;1.52</td><td align="left" colspan="1" rowspan="1">2.52&#8201;&#177;&#8201;1.76</td><td align="left" colspan="1" rowspan="1">0.75</td></tr><tr><td align="left" colspan="1" rowspan="1">NRS &#8212; POD1 mean</td><td align="left" colspan="1" rowspan="1">1.73&#8201;&#177;&#8201;0.73</td><td align="left" colspan="1" rowspan="1">1.41&#8201;&#177;&#8201;0.76</td><td align="left" colspan="1" rowspan="1">0.02</td></tr><tr><td align="left" colspan="1" rowspan="1">NRS &#8212; POD2 mean</td><td align="left" colspan="1" rowspan="1">1.62&#8201;&#177;&#8201;0.71</td><td align="left" colspan="1" rowspan="1">1.34&#8201;&#177;&#8201;0.79</td><td align="left" colspan="1" rowspan="1">0.03</td></tr><tr><td align="left" colspan="1" rowspan="1">Antiemetic prescription (inpatient)</td><td align="left" colspan="1" rowspan="1">19 (19.79%)</td><td align="left" colspan="1" rowspan="1">11 (26.19%)</td><td align="left" colspan="1" rowspan="1">0.40</td></tr><tr><td align="left" colspan="1" rowspan="1">ED readmission &#8212; any</td><td align="left" colspan="1" rowspan="1">13 (13.54%)</td><td align="left" colspan="1" rowspan="1">9 (21.43%)</td><td align="left" colspan="1" rowspan="1">0.24</td></tr><tr><td align="left" colspan="1" rowspan="1">ED readmission &#8212; pain&#8209;related</td><td align="left" colspan="1" rowspan="1">5 (5.21%)</td><td align="left" colspan="1" rowspan="1">4 (9.52%)</td><td align="left" colspan="1" rowspan="1">0.46</td></tr><tr><td align="left" colspan="1" rowspan="1">ED readmission &#8212; bleeding&#8209;related</td><td align="left" colspan="1" rowspan="1">9 (9.38%)</td><td align="left" colspan="1" rowspan="1">8 (19.05%)</td><td align="left" colspan="1" rowspan="1">0.11</td></tr><tr><td align="left" colspan="1" rowspan="1">ED readmission &#8212; nausea&#8209;related</td><td align="left" colspan="1" rowspan="1">0 (0.00%)</td><td align="left" colspan="1" rowspan="1">0 (0.00%)</td><td align="left" colspan="1" rowspan="1">N/A</td></tr><tr><td align="left" colspan="1" rowspan="1">Rehospitalization (any)</td><td align="left" colspan="1" rowspan="1">0 (0.00%)</td><td align="left" colspan="1" rowspan="1">2 (4.76%)</td><td align="left" colspan="1" rowspan="1">0.09</td></tr></tbody></table><table-wrap-foot><p>One patient in the DNS group had missing data for volatile agent usage</p><p>This missing case was excluded from the statistical analysis</p><p><italic toggle="yes">NRS</italic> Numeric rating scale, <italic toggle="yes">ED</italic> Emergency department</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec15"><title>Adverse events between the DNS and CA groups</title><p id="Par24">In the safety domain, Table&#160;<xref rid="Tab4" ref-type="table">4</xref> summarizes antiemetic prescribing as an indirect assessment of postoperative nausea and vomiting (PONV). Antiemetics were administered to 19 patients (19.79%) in the DNS group and 11 patients (26.19%) in the CA group, with no statistically significant difference (<italic toggle="yes">p</italic>&#8201;=&#8201;0.402). Table <xref rid="Tab4" ref-type="table">4</xref> also compares emergency department (ED) revisits and unplanned rehospitalizations attributable to postoperative complications. Overall, ED revisit rates were 13.54% (DNS) versus 21.43% (CA) (<italic toggle="yes">p</italic>&#8201;=&#8201;0.244); pain-related ED revisits were 5.21% versus 9.52% (<italic toggle="yes">p</italic>&#8201;=&#8201;0.455); and bleeding-related ED revisits were 9.38% versus 19.05% (<italic toggle="yes">p</italic>&#8201;=&#8201;0.111). No nausea-related ED revisits were observed in either cohort. Unplanned rehospitalization occurred in 0% of the DNS group versus 4.76% of the CA group (<italic toggle="yes">p</italic>&#8201;=&#8201;0.091).</p></sec></sec><sec id="Sec16"><title>Post hoc analysis</title><p id="Par25">A post hoc analysis was conducted to evaluate the potential confounding effect of parecoxib dosages. To account for the confounding influence of parecoxib, multivariable logistic regression was performed. Parecoxib dosage was stratified into low-dose (&#8804;&#8201;120&#160;mg) and high-dose (&gt;&#8201;120&#160;mg) groups based on the overall mean dosage of 119.71&#160;mg. In the multivariable model (Table&#160;<xref rid="Tab5" ref-type="table">5</xref>), DNS administration remained significantly associated with reduced inpatient opioid prescription (OR&#8201;=&#8201;0.378, 95% CI: 0.172&#8211;0.834, <italic toggle="yes">p</italic>&#8201;=&#8201;0.016). However, high-dose parecoxib did not show a significant independent effect on inpatient opioid prescription reduction (OR&#8201;=&#8201;0.847, 95% CI: 0.391&#8211;1.835, <italic toggle="yes">p</italic>&#8201;=&#8201;0.673).
<table-wrap id="Tab5" position="float" orientation="portrait"><label>Table&#160;5</label><caption><p>Multivariable logistic regression for the analysis of inpatient opioid prescriptions</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Variable</th><th align="left" colspan="1" rowspan="1">Odds ratio</th><th align="left" colspan="1" rowspan="1">95% Confidence interval</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Dinalbuphine sebacate</td><td char="." align="char" colspan="1" rowspan="1">0.378</td><td char="&#x2013;" align="char" colspan="1" rowspan="1">0.172&#8211;0.834</td><td char="." align="char" colspan="1" rowspan="1">0.02</td></tr><tr><td align="left" colspan="1" rowspan="1">High-dose parecoxib</td><td char="." align="char" colspan="1" rowspan="1">0.847</td><td char="&#x2013;" align="char" colspan="1" rowspan="1">0.391&#8211;1.835</td><td char="." align="char" colspan="1" rowspan="1">0.67</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="Sec17"><title>Discussion</title><p id="Par26">To our knowledge, this is the first observational study to characterize perioperative analgesic dosing in a cohort undergoing multilevel sleep surgery performed entirely via a transoral robotic approach (TORS). Compared with conventional UPPP or UPPP plus tongue-base radiofrequency, the robotic platform is specifically engineered to facilitate the precise resection of deep-seated tissue within a narrow operative corridor, which typically results in larger and deeper tongue-base defects than earlier techniques. Consequently, the postoperative pain burden in this cohort would be expected to be at least comparable to&#8212;if not greater than&#8212;that observed after traditional procedures.</p><p id="Par27">Our study demonstrated that, compared to the CA group, DNS significantly reduced short-term postoperative opioid requirements while maintaining comparable analgesic efficacy. However, patients in the DNS group exhibited a significantly higher mean NRS pain score on POD1 (1.73&#8201;&#177;&#8201;0.72 vs. 1.41&#8201;&#177;&#8201;0.76, <italic toggle="yes">p</italic>&#8201;=&#8201;0.025) and POD2 (1.62&#8201;&#177;&#8201;0.71 vs. 1.34&#8201;&#177;&#8201;0.79; <italic toggle="yes">p</italic>&#8201;=&#8201;0.031). Despite statistical significance, the absolute differences were only 0.32 and 0.27, which were unlikely to be clinically meaningful. This discrepancy may be attributed to the influence of extreme values. Given the minimal numerical difference, this finding may not suggest a substantial difference in actual pain perception between the groups. Similarly, we observed that the DNS group had significantly higher OME doses in the PACU. However, the absolute difference was only 1.82&#160;mg, which is also unlikely to have clinical significance.</p><p id="Par28">We observed that the cumulative doses of various analgesics, except for parecoxib, were significantly lower in the DNS group. Post hoc analyses further indicated that while higher cumulative doses of parecoxib were associated with a trend toward reducing post-operative opioid requirements, this effect did not reach statistical significance (OR: 0.847, 95% CI: 0.391&#8211;1.835, p&#8201;=&#8201;0.673). Therefore, parecoxib cannot be considered a significant confounding factor in assessing the effects of DNS. Nevertheless, these findings suggest a potential synergistic interaction between DNS and parecoxib, which may contribute to the overall reduction in cumulative analgesic consumption. Previous studies have demonstrated that parecoxib effectively reduces both resting and swallowing pain visual-analog-scale (VAS) scores within 48&#160;h of UPPP without inducing respiratory depression [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. This characteristic may further enhance the analgesic efficacy of DNS. However, the combined use of DNS and parecoxib as part of an MMA regimen requires further validation through larger, multicenter clinical trials in order to establish its clinical relevance and optimize postoperative pain management strategies.</p><p id="Par29">Compared with conventional analgesia, DNS was associated with a 24.6% absolute and &#8776;45% relative reduction in any inpatient opioid exposure (NNT &#8776; 4), a 19.4% absolute reduction in discharge opioid prescribing (NNT &#8776; 5), and a 38.8% absolute reduction at the first outpatient follow-up (NNT &#8776; 3) (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>). DNS also reduced inpatient OME by &#8776;41&#160;mg on average (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>), a &#8776;73% relative decrease. Although mean NRS values on POD1&#8211;2 were modestly lower in the CA cohort (between-group differences&#8201;&#8804;&#8201;0.32 points), these differences fall below commonly cited minimal clinically important thresholds for acute postoperative pain, suggesting limited clinical salience. Safety outcomes (ED revisits, unplanned rehospitalizations) did not differ significantly (Table&#160;<xref rid="Tab4" ref-type="table">4</xref>). In aggregate, the data support clinically meaningful opioid stewardship without compromising analgesia to a degree likely to be meaningful to patients. These findings exhibited reduced opioid requirements at discharge and during the first follow-up outpatient visit. Among discharged patients, 68.75% received opioid prescriptions, which aligns with the prescription patterns identified in a previous large retrospective study [<xref ref-type="bibr" rid="CR26">26</xref>]. Evidence suggests that sleep surgeons tend to prescribe opioids to UPPP patients postoperatively [<xref ref-type="bibr" rid="CR27">27</xref>]. While this trend may be partly attributed to physician preferences, reduced opioid prescriptions in the DNS group could reflect adequate analgesia achieved by this regimen, thereby decreasing postoperative opioid consumption and prescription. Reducing initial opioid prescriptions may mitigate opioid reliance, conferring additional benefits to patients [<xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par30">The overall ED readmission rate after discharge was 16.67% (22/132), consistent with prior studies [<xref ref-type="bibr" rid="CR28">28</xref>]. Of these, 9 patients (6.82%) were readmitted due to pain, and 17 patients (12.88%) were readmitted due to bleeding, highlighting that uncontrolled pain and bleeding remain critical concerns after UPPP surgery. While ER readmission rates did not differ significantly between the two groups, the DNS group exhibited a lower proportion of pain-related ER readmissions (5.21% vs. 9.52%). This difference, although not statistically significant, may warrant further exploration in studies with larger sample sizes in order to realize adequate statistical power. Notably, in the CA group, two patients required re-hospitalization. One was readmitted for pain management and received analgesic treatment. The other patient was readmitted due to a combination of pain and bleeding and underwent observation, hemostatic intervention, and analgesic treatment. No patients in the DNS group experienced rehospitalization.</p><p id="Par31">Adverse events associated with DNS, such as dizziness, nausea, and vomiting, were frequently reported in previous studies [<xref ref-type="bibr" rid="CR16">16</xref>]. In our study, the rates of antiemetic use during hospitalization did not differ significantly between the DNS and CA groups. Most patients received a single dose of antiemetic medication only on the day of surgery, and none required further treatment for dizziness, nausea, or vomiting after discharge.</p><p id="Par32">Several analgesics, such as ketorolac [<xref ref-type="bibr" rid="CR29">29</xref>] and celecoxib [<xref ref-type="bibr" rid="CR30">30</xref>], have been shown to reduce postoperative opioid consumption and requirement in UPPP patients. Compared to these medications, DNS offers notable convenience. Unlike usual enhanced recovery after surgery (ERAS) protocols, which often involve a combination of multiple administrative routes&#8212;such as local anesthetic infiltration, parenteral analgesics, and oral analgesics&#8212;DNS relies solely on single intramuscular injections, simplifying drug administration. Additionally, DNS provides prolonged drug release lasting up to 145.2&#160;h, reducing the frequency of medical interventions for pain relief. DNS has demonstrated significant postoperative analgesic effects in various surgeries, including hemorrhoidectomy [<xref ref-type="bibr" rid="CR31">31</xref>] and laparoscopic bariatric surgery [<xref ref-type="bibr" rid="CR32">32</xref>]. However, its application in otolaryngological surgeries remains underexplored. Our study provides preliminary evidence supporting the use of DNS in this field.</p><p id="Par33">Regarding the clinical application and adaptability of this study, our results should be interpreted in the context of current guidance for OSA/OSAHS surgical patients. ASA and SASM recommendations highlight the need to limit systemic opioids, prioritize non-opioid multimodal analgesia, and implement appropriate postoperative monitoring in OSA [<xref ref-type="bibr" rid="CR20">20</xref>]. The AAO-HNSF guideline similarly promotes judicious opioid prescribing after ENT procedures [<xref ref-type="bibr" rid="CR21">21</xref>]. Evidence from TORS-focused ERAS pathways shows that structured multimodal protocols reduce opioid exposure and improve pain outcomes [<xref ref-type="bibr" rid="CR19">19</xref>]. Against this backdrop, the observed association between DNS use and lower inpatient opioid exposure and reduced discharge opioid prescribing suggests that incorporating a long-acting opioid-sparing component within a comprehensive multimodal pathway may help operationalize these recommendations in TORS-UPPP programs. At the same time, institutions should tailor implementation to local resources and maintain vigilance for respiratory risk in OSA, consistent with guideline cautions [<xref ref-type="bibr" rid="CR33">33</xref>].</p><p id="Par34">This study has several limitations. First, due to its retrospective design, we could only minimize and evaluate the impact of confounding factors through patient selection and post hoc analyses. Although logistic regression analysis indicated that parecoxib did not significantly influence the reduction in opioid consumption during the first two postoperative days, unmeasured confounding factors might still exist. Future studies should explore the role of parecoxib more thoroughly and employ stricter statistical controls in order to validate more true effects of DNS. Second, the use of DNS was based on patient preference rather than random assignment, patients with better financial status or greater pain sensitivity may have been more likely to choose DNS. Moreover, variations in physicians&#8217; recommendations for DNS could have resulted in an uneven distribution of patients across different surgeons, potentially influencing surgical factors. These issues may affect the interpretation of our findings and highlight the need for future randomized controlled trials to confirm the results. Third, the overall sample size was limited due to the retrospective design. Some findings, such as differences in pain-related ER readmission rates, may have been affected by inadequate statistical power. These results do not necessarily reflect the absence of a true effect but rather the limitations of sample size. Future research with larger cohorts is necessary to clarify these observations. Otherwise, the NRS assessments in this study were conducted at different time points and by different nurses. In future research, pain assessments should be further standardized to enhance inter-rater reliability. Finally, the study population was restricted to a single medical center. To enhance the external validity of DNS in postoperative pain management after UPPP, future multi-center randomized controlled trials are recommended to evaluate its application across diverse medical settings and compare its efficacy with other analgesic strategies.</p></sec><sec id="Sec18"><title>Conclusions</title><p id="Par35">A single dose of DNS (150&#160;mg) administered at anesthesia induction significantly reduced the OME doses from POD0 to POD2 after the patient&#8217;s return to the ward, providing analgesic efficacy comparable to that of conventional protocols. Furthermore, a second dose of DNS administered 5&#8211;7&#160;days postoperatively significantly reduced opioid prescriptions at discharge and during the first outpatient follow-up. There were no significant differences in ED readmission rates due to pain, bleeding, or nausea between the DNS and CA groups. Combining DNS with parecoxib may offer a more effective analgesic strategy for UPPP patients, warranting further investigation in randomized controlled trials.</p></sec><sec id="Sec19" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11701_2025_2829_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary file1 (DOCX 17 KB)</p></caption></media></supplementary-material></p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Cheng-Wei Li and Chien-Han Tsao have contributed equally to this work as first authors.</p></fn><fn><p>Yueh-Hsien Hsu and Chien-Han Tsao have contributed equally as corresponding authors.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Conflicts of Interest: The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Conceptualization: Chien-Han Tsao, Cheng-Wei Li. Data curation: Chien-Han Tsao. Formal analysis: Cheng-Wei Li. Funding acquisition: Yueh-Hsien Hsu. Investigation: Cheng-Wei Li, Chien-Han Tsao. Methodology: Cheng-Wei Li, Chien-Han Tsao. Project administration: Chien-Han Tsao. Resources: Chien-Han Tsao. Software: Cheng-Wei Li. Supervision: Yueh-Hsien Hsu, Chien-Han Tsao. Validation: Cheng-Wei Li. Visualization: Cheng-Wei Li. Writing&#8212;original draft: Cheng-Wei Li. Writing&#8212;review &amp; editing: Chien-Han Tsao, Yueh-Hsien Hsu.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study was funded by a research grant of NT$80,000 from the Department of Medical Research, Chung Shan Medical University Hospital (Grant Number: CSH-2025-A-010).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The raw data supporting the conclusions of this article will be made available by the corresponding authors upon request.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par36">The authors declare no competing interests.</p></notes><notes id="FPar2"><title>Institutional review board statement</title><p id="Par37">This study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board (name of institution blinded for review) (IRB number: CS1-24073).</p></notes><notes id="FPar3"><title>Informed consent</title><p id="Par38">The requirement for informed consent was waived because of the retrospective design of the study.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iannella</surname><given-names>G</given-names></name><name name-style="western"><surname>Pace</surname><given-names>A</given-names></name><name name-style="western"><surname>Bellizzi</surname><given-names>MG</given-names></name><name name-style="western"><surname>Magliulo</surname><given-names>G</given-names></name><name name-style="western"><surname>Greco</surname><given-names>A</given-names></name><name name-style="western"><surname>De Virgilio</surname><given-names>A</given-names></name><name name-style="western"><surname>Croce</surname><given-names>E</given-names></name><name name-style="western"><surname>Gioacchini</surname><given-names>FM</given-names></name><name name-style="western"><surname>Re</surname><given-names>M</given-names></name><name name-style="western"><surname>Costantino</surname><given-names>A</given-names></name><name name-style="western"><surname>Casale</surname><given-names>M</given-names></name><name name-style="western"><surname>Moffa</surname><given-names>A</given-names></name><name name-style="western"><surname>Lechien</surname><given-names>JR</given-names></name><name name-style="western"><surname>Cocuzza</surname><given-names>S</given-names></name><name name-style="western"><surname>Vicini</surname><given-names>C</given-names></name><name name-style="western"><surname>Caranti</surname><given-names>A</given-names></name><name name-style="western"><surname>Marchese Aragona</surname><given-names>R</given-names></name><name name-style="western"><surname>Lentini</surname><given-names>M</given-names></name><name name-style="western"><surname>Maniaci</surname><given-names>A</given-names></name></person-group><article-title>The global burden of obstructive sleep apnea</article-title><source>Diagnostics</source><year>2025</year><volume>15</volume><fpage>1088</fpage><pub-id pub-id-type="doi">10.3390/diagnostics15091088</pub-id><pub-id pub-id-type="pmid">40361906</pub-id><pub-id pub-id-type="pmcid">PMC12071658</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Iannella G, Pace A, Bellizzi MG, Magliulo G, Greco A, De Virgilio A, Croce E, Gioacchini FM, Re M, Costantino A, Casale M, Moffa A, Lechien JR, Cocuzza S, Vicini C, Caranti A, Marchese Aragona R, Lentini M, Maniaci A (2025) The global burden of obstructive sleep apnea. Diagnostics 15:1088. 10.3390/diagnostics15091088. (<bold>PMID: 40361906; PMCID: PMC12071658</bold>)<pub-id pub-id-type="pmid">40361906</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/diagnostics15091088</pub-id><pub-id pub-id-type="pmcid">PMC12071658</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wickwire</surname><given-names>EM</given-names></name></person-group><article-title>Value-based sleep and breathing: health economic aspects of obstructive sleep apnea</article-title><source>Fac Rev</source><year>2021</year><volume>10</volume><fpage>40</fpage><pub-id pub-id-type="doi">10.12703/r/10-40</pub-id><pub-id pub-id-type="pmid">34046644</pub-id><pub-id pub-id-type="pmcid">PMC8130410</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Wickwire EM (2021) Value-based sleep and breathing: health economic aspects of obstructive sleep apnea. Fac Rev 10:40. 10.12703/r/10-40. (<bold>PMID: 34046644</bold>)<pub-id pub-id-type="pmid">34046644</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.12703/r/10-40</pub-id><pub-id pub-id-type="pmcid">PMC8130410</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Friedman</surname><given-names>M</given-names></name><name name-style="western"><surname>Hamilton</surname><given-names>C</given-names></name><name name-style="western"><surname>Samuelson</surname><given-names>CG</given-names></name><name name-style="western"><surname>Kelley</surname><given-names>K</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>D</given-names></name><name name-style="western"><surname>Pearson-Chauhan</surname><given-names>K</given-names></name><etal/></person-group><article-title>Transoral robotic glossectomy for the treatment of obstructive sleep apnea-hypopnea syndrome</article-title><source>Otolaryngol Head Neck Surg</source><year>2012</year><volume>146</volume><issue>5</issue><fpage>854</fpage><lpage>862</lpage><pub-id pub-id-type="doi">10.1177/0194599811434262</pub-id><pub-id pub-id-type="pmid">22247514</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Friedman M, Hamilton C, Samuelson CG, Kelley K, Taylor D, Pearson-Chauhan K et al (2012) Transoral robotic glossectomy for the treatment of obstructive sleep apnea-hypopnea syndrome. Otolaryngol Head Neck Surg 146(5):854&#8211;862. 10.1177/0194599811434262. (<bold>PMID: 22247514</bold>)<pub-id pub-id-type="pmid">22247514</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0194599811434262</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meccariello</surname><given-names>G</given-names></name><name name-style="western"><surname>Cammaroto</surname><given-names>G</given-names></name><name name-style="western"><surname>Montevecchi</surname><given-names>F</given-names></name><name name-style="western"><surname>Hoff</surname><given-names>PT</given-names></name><name name-style="western"><surname>Spector</surname><given-names>ME</given-names></name><name name-style="western"><surname>Negm</surname><given-names>H</given-names></name><name name-style="western"><surname>Shams</surname><given-names>M</given-names></name><name name-style="western"><surname>Bellini</surname><given-names>C</given-names></name><name name-style="western"><surname>Zeccardo</surname><given-names>E</given-names></name><name name-style="western"><surname>Vicini</surname><given-names>C</given-names></name></person-group><article-title>Transoral robotic surgery for the management of obstructive sleep apnea: a systematic review and meta-analysis</article-title><source>Eur Arch Otorhinolaryngol</source><year>2017</year><volume>274</volume><fpage>647</fpage><lpage>653</lpage><pub-id pub-id-type="doi">10.1007/s00405-016-4113-3</pub-id><pub-id pub-id-type="pmid">27221389</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Meccariello G, Cammaroto G, Montevecchi F, Hoff PT, Spector ME, Negm H, Shams M, Bellini C, Zeccardo E, Vicini C (2017) Transoral robotic surgery for the management of obstructive sleep apnea: a systematic review and meta-analysis. Eur Arch Otorhinolaryngol 274:647&#8211;653. 10.1007/s00405-016-4113-3. (<bold>PMID: 27221389</bold>)<pub-id pub-id-type="pmid">27221389</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00405-016-4113-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsou</surname><given-names>YA</given-names></name><name name-style="western"><surname>Chang</surname><given-names>WD</given-names></name></person-group><article-title>Comparison of transoral robotic surgery with other surgeries for obstructive sleep apnea</article-title><source>Sci Rep</source><year>2020</year><volume>10</volume><issue>1</issue><fpage>18163</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-75215-1</pub-id><pub-id pub-id-type="pmid">33097783</pub-id><pub-id pub-id-type="pmcid">PMC7585414</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Tsou YA, Chang WD (2020) Comparison of transoral robotic surgery with other surgeries for obstructive sleep apnea. Sci Rep 10(1):18163. 10.1038/s41598-020-75215-1. (<bold>PMID: 33097783; PMCID: PMC7585414</bold>)<pub-id pub-id-type="pmid">33097783</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-020-75215-1</pub-id><pub-id pub-id-type="pmcid">PMC7585414</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Snyder</surname><given-names>V</given-names></name><name name-style="western"><surname>Kraft</surname><given-names>DO</given-names></name><name name-style="western"><surname>Creamer</surname><given-names>A</given-names></name><name name-style="western"><surname>Spector</surname><given-names>ME</given-names></name><name name-style="western"><surname>Sridharan</surname><given-names>SS</given-names></name></person-group><article-title>A scoping review of pain management after transoral robotic surgery</article-title><source>Otolaryngol Head Neck Surg</source><year>2024</year><volume>171</volume><fpage>1617</fpage><lpage>1627</lpage><pub-id pub-id-type="doi">10.1002/ohn.871</pub-id><pub-id pub-id-type="pmid">39031715</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Snyder V, Kraft DO, Creamer A, Spector ME, Sridharan SS (2024) A scoping review of pain management after transoral robotic surgery. Otolaryngol Head Neck Surg 171:1617&#8211;1627. 10.1002/ohn.871. (<bold>PMID: 39031715</bold>)<pub-id pub-id-type="pmid">39031715</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ohn.871</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Topf</surname><given-names>MC</given-names></name><name name-style="western"><surname>Vo</surname><given-names>A</given-names></name><name name-style="western"><surname>Tassone</surname><given-names>P</given-names></name><name name-style="western"><surname>Shumrick</surname><given-names>C</given-names></name><name name-style="western"><surname>Luginbuhl</surname><given-names>A</given-names></name><name name-style="western"><surname>Cognetti</surname><given-names>DM</given-names></name><name name-style="western"><surname>Curry</surname><given-names>JM</given-names></name></person-group><article-title>Unplanned readmission following transoral robotic surgery</article-title><source>Oral Oncol</source><year>2017</year><volume>75</volume><fpage>127</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1016/j.oraloncology.2017.11.009</pub-id><pub-id pub-id-type="pmid">29224809</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Topf MC, Vo A, Tassone P, Shumrick C, Luginbuhl A, Cognetti DM, Curry JM (2017) Unplanned readmission following transoral robotic surgery. Oral Oncol 75:127&#8211;132. 10.1016/j.oraloncology.2017.11.009. (<bold>PMID: 29224809</bold>)<pub-id pub-id-type="pmid">29224809</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.oraloncology.2017.11.009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glazer</surname><given-names>TA</given-names></name><name name-style="western"><surname>Hoff</surname><given-names>PT</given-names></name><name name-style="western"><surname>Spector</surname><given-names>ME</given-names></name></person-group><article-title>Transoral robotic surgery for obstructive sleep apnea: perioperative management and postoperative complications</article-title><source>JAMA Otolaryngol Head Neck Surg</source><year>2014</year><volume>140</volume><fpage>1207</fpage><lpage>1212</lpage><pub-id pub-id-type="doi">10.1001/jamaoto.2014.2299</pub-id><pub-id pub-id-type="pmid">25275670</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Glazer TA, Hoff PT, Spector ME (2014) Transoral robotic surgery for obstructive sleep apnea: perioperative management and postoperative complications. JAMA Otolaryngol Head Neck Surg 140:1207&#8211;1212. 10.1001/jamaoto.2014.2299. (<bold>PMID: 25275670</bold>)<pub-id pub-id-type="pmid">25275670</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoto.2014.2299</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Driver</surname><given-names>CN</given-names></name><name name-style="western"><surname>Laporta</surname><given-names>ML</given-names></name><name name-style="western"><surname>Bergese</surname><given-names>SD</given-names></name><name name-style="western"><surname>Urman</surname><given-names>RD</given-names></name><name name-style="western"><surname>Di Piazza</surname><given-names>F</given-names></name><name name-style="western"><surname>Overdyk</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Sprung</surname><given-names>J</given-names></name><name name-style="western"><surname>Weingarten</surname><given-names>TN</given-names></name></person-group><article-title>Frequency and temporal distribution of postoperative respiratory depressive events</article-title><source>Anesth Analg</source><year>2021</year><volume>132</volume><issue>5</issue><fpage>1206</fpage><lpage>1214</lpage><pub-id pub-id-type="doi">10.1213/ANE.0000000000005478</pub-id><pub-id pub-id-type="pmid">33857962</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Driver CN, Laporta ML, Bergese SD, Urman RD, Di Piazza F, Overdyk FJ, Sprung J, Weingarten TN (2021) Frequency and temporal distribution of postoperative respiratory depressive events. Anesth Analg 132(5):1206&#8211;1214. 10.1213/ANE.0000000000005478. (<bold>PMID: 33857962</bold>)<pub-id pub-id-type="pmid">33857962</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1213/ANE.0000000000005478</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdelwahab</surname><given-names>M</given-names></name><name name-style="western"><surname>Marques</surname><given-names>S</given-names></name><name name-style="western"><surname>Howard</surname><given-names>J</given-names></name><name name-style="western"><surname>Huang</surname><given-names>A</given-names></name><name name-style="western"><surname>Lechner</surname><given-names>M</given-names></name><name name-style="western"><surname>Olds</surname><given-names>C</given-names></name><name name-style="western"><surname>Capasso</surname><given-names>R</given-names></name></person-group><article-title>Incidence and risk factors of chronic opioid use after sleep apnea surgery</article-title><source>J Clin Sleep Med</source><year>2022</year><volume>18</volume><issue>7</issue><fpage>1805</fpage><lpage>1813</lpage><pub-id pub-id-type="doi">10.5664/jcsm.9978</pub-id><pub-id pub-id-type="pmid">35393936</pub-id><pub-id pub-id-type="pmcid">PMC9243273</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Abdelwahab M, Marques S, Howard J, Huang A, Lechner M, Olds C, Capasso R (2022) Incidence and risk factors of chronic opioid use after sleep apnea surgery. J Clin Sleep Med 18(7):1805&#8211;1813. 10.5664/jcsm.9978. (<bold>PMID: 35393936; PMCID: PMC9243273</bold>)<pub-id pub-id-type="pmid">35393936</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5664/jcsm.9978</pub-id><pub-id pub-id-type="pmcid">PMC9243273</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stewart</surname><given-names>M</given-names></name><name name-style="western"><surname>Mastrolonardo</surname><given-names>E</given-names></name><name name-style="western"><surname>Ghias</surname><given-names>A</given-names></name><name name-style="western"><surname>Butkus</surname><given-names>J</given-names></name><name name-style="western"><surname>Hobelmann</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>T</given-names></name><name name-style="western"><surname>Dang</surname><given-names>S</given-names></name><name name-style="western"><surname>Cognetti</surname><given-names>D</given-names></name><name name-style="western"><surname>Rosen</surname><given-names>D</given-names></name><name name-style="western"><surname>Boon</surname><given-names>M</given-names></name><etal/></person-group><article-title>Opioid usage and pain control in benign oropharyngeal surgery: an observational prospective study</article-title><source>Ann Otol Rhinol Lar-yngol</source><year>2022</year><volume>131</volume><fpage>1060</fpage><lpage>1067</lpage><pub-id pub-id-type="doi">10.1177/00034894211053290</pub-id><pub-id pub-id-type="pmid">34694150</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Stewart M, Mastrolonardo E, Ghias A, Butkus J, Hobelmann K, Zhan T, Dang S, Cognetti D, Rosen D, Boon M et al (2022) Opioid usage and pain control in benign oropharyngeal surgery: an observational prospective study. Ann Otol Rhinol Lar-yngol 131:1060&#8211;1067. 10.1177/00034894211053290. (<bold>PMID: 34694150</bold>)<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/00034894211053290</pub-id><pub-id pub-id-type="pmid">34694150</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cozowicz</surname><given-names>C</given-names></name><name name-style="western"><surname>Chung</surname><given-names>F</given-names></name><name name-style="western"><surname>Doufas</surname><given-names>AG</given-names></name><name name-style="western"><surname>Nagappa</surname><given-names>M</given-names></name><name name-style="western"><surname>Memtsoudis</surname><given-names>SG</given-names></name></person-group><article-title>Opioids for acute pain management in patients with obstructive sleep apnea: a systematic review</article-title><source>Anesth Analg</source><year>2018</year><volume>127</volume><fpage>988</fpage><lpage>1001</lpage><pub-id pub-id-type="doi">10.1213/ANE.0000000000003549</pub-id><pub-id pub-id-type="pmid">29958218</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Cozowicz C, Chung F, Doufas AG, Nagappa M, Memtsoudis SG (2018) Opioids for acute pain management in patients with obstructive sleep apnea: a systematic review. Anesth Analg 127:988&#8211;1001. 10.1213/ANE.0000000000003549. (<bold>PMID: 29958218</bold>)<pub-id pub-id-type="pmid">29958218</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1213/ANE.0000000000003549</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anne</surname><given-names>S</given-names></name><name name-style="western"><surname>Mims</surname><given-names>JW</given-names></name><name name-style="western"><surname>Tunkel</surname><given-names>DE</given-names></name><name name-style="western"><surname>Rosenfeld</surname><given-names>RM</given-names></name><name name-style="western"><surname>Boisoneau</surname><given-names>DS</given-names></name><name name-style="western"><surname>Brenner</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Cramer</surname><given-names>JD</given-names></name><name name-style="western"><surname>Dickerson</surname><given-names>D</given-names></name><name name-style="western"><surname>Finestone</surname><given-names>SA</given-names></name><name name-style="western"><surname>Folbe</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Clinical practice guideline: opioid prescribing for analgesia after common otolaryngology operations</article-title><source>Oto-laryngol Head Neck Surg</source><year>2021</year><volume>164</volume><issue>Suppl. S2</issue><fpage>S1</fpage><lpage>S42</lpage><pub-id pub-id-type="doi">10.1177/0194599821996297</pub-id><pub-id pub-id-type="pmid">33822668</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Anne S, Mims JW, Tunkel DE, Rosenfeld RM, Boisoneau DS, Brenner MJ, Cramer JD, Dickerson D, Finestone SA, Folbe AJ et al (2021) Clinical practice guideline: opioid prescribing for analgesia after common otolaryngology operations. Oto-laryngol Head Neck Surg 164(Suppl. S2):S1&#8211;S42. 10.1177/0194599821996297. (<bold>PMID: 33822668</bold>)<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0194599821996297</pub-id><pub-id pub-id-type="pmid">33822668</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tien</surname><given-names>YE</given-names></name><name name-style="western"><surname>Huang</surname><given-names>WC</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>HY</given-names></name><name name-style="western"><surname>Tai</surname><given-names>L</given-names></name><name name-style="western"><surname>Uang</surname><given-names>YS</given-names></name><name name-style="western"><surname>Chern</surname><given-names>WH</given-names></name><name name-style="western"><surname>Huang</surname><given-names>JD</given-names></name></person-group><article-title>Pharmacokinetics of dinalbuphine sebacate and nalbuphine in human after intramuscular injection of dinalbuphine sebacate in an extended-release formulation</article-title><source>Biopharm Drug Dispos</source><year>2017</year><volume>38</volume><fpage>494</fpage><lpage>497</lpage><pub-id pub-id-type="doi">10.1002/bdd.2088</pub-id><pub-id pub-id-type="pmid">28741675</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Tien YE, Huang WC, Kuo HY, Tai L, Uang YS, Chern WH, Huang JD (2017) Pharmacokinetics of dinalbuphine sebacate and nalbuphine in human after intramuscular injection of dinalbuphine sebacate in an extended-release formulation. Biopharm Drug Dispos 38:494&#8211;497. 10.1002/bdd.2088. (<bold>PMID: 28741675</bold>)<pub-id pub-id-type="pmid">28741675</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/bdd.2088</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>ZH</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>TT</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>CC</given-names></name><name name-style="western"><surname>Lin</surname><given-names>PA</given-names></name><name name-style="western"><surname>Wong</surname><given-names>CS</given-names></name><name name-style="western"><surname>Lee</surname><given-names>PY</given-names></name><name name-style="western"><surname>Lu</surname><given-names>CH</given-names></name></person-group><article-title>Multimodal analgesia with extended-release Di-nalbuphine sebacate for perioperative pain management in upper extremity trauma surgery: a retrospective comparative study</article-title><source>Pain Ther</source><year>2022</year><volume>11</volume><fpage>643</fpage><lpage>653</lpage><pub-id pub-id-type="doi">10.1007/s40122-022-00383-z</pub-id><pub-id pub-id-type="pmid">35426567</pub-id><pub-id pub-id-type="pmcid">PMC9098781</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Zheng ZH, Yeh TT, Yeh CC, Lin PA, Wong CS, Lee PY, Lu CH (2022) Multimodal analgesia with extended-release Di-nalbuphine sebacate for perioperative pain management in upper extremity trauma surgery: a retrospective comparative study. Pain Ther 11:643&#8211;653. 10.1007/s40122-022-00383-z. (<bold>PMID: 35426567; PMCID: PMC9098781</bold>)<pub-id pub-id-type="pmid">35426567</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40122-022-00383-z</pub-id><pub-id pub-id-type="pmcid">PMC9098781</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>SO</given-names></name><name name-style="western"><surname>Huang</surname><given-names>LP</given-names></name><name name-style="western"><surname>Wong</surname><given-names>CS</given-names></name></person-group><article-title>Preoperative administration of extended-release dinalbuphine sebacate compares with morphine for post-laparoscopic cholecystectomy pain management: a randomized study</article-title><source>J Pain Res</source><year>2020</year><volume>13</volume><fpage>2247</fpage><lpage>2253</lpage><pub-id pub-id-type="doi">10.2147/JPR.S263315</pub-id><pub-id pub-id-type="pmid">32982387</pub-id><pub-id pub-id-type="pmcid">PMC7490073</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Lee SO, Huang LP, Wong CS (2020) Preoperative administration of extended-release dinalbuphine sebacate compares with morphine for post-laparoscopic cholecystectomy pain management: a randomized study. J Pain Res 13:2247&#8211;2253. 10.2147/JPR.S263315. (<bold>PMID: 32982387; PMCID: PMC7490073</bold>)<pub-id pub-id-type="pmid">32982387</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/JPR.S263315</pub-id><pub-id pub-id-type="pmcid">PMC7490073</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>SO</given-names></name><name name-style="western"><surname>Lu</surname><given-names>CH</given-names></name><name name-style="western"><surname>Man</surname><given-names>KM</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>KI</given-names></name><name name-style="western"><surname>Wong</surname><given-names>CS</given-names></name><name name-style="western"><surname>Sun</surname><given-names>WZ</given-names></name></person-group><article-title>Multimodal analgesia with extended-release dinalbuphine sebacate for perioperative management: expert opinion and consensus</article-title><source>Asian J Anesthesiol</source><year>2023</year><volume>61</volume><fpage>123</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.6859/aja.202309_61(3).0004</pub-id><pub-id pub-id-type="pmid">38320858</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Lee SO, Lu CH, Man KM, Cheng KI, Wong CS, Sun WZ (2023) Multimodal analgesia with extended-release dinalbuphine sebacate for perioperative management: expert opinion and consensus. Asian J Anesthesiol 61:123&#8211;131. 10.6859/aja.202309_61(3).0004. (<bold>PMID: 38320858</bold>)<pub-id pub-id-type="pmid">38320858</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.6859/aja.202309_61(3).0004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castellanos</surname><given-names>CX</given-names></name><name name-style="western"><surname>Paoletti</surname><given-names>M</given-names></name><name name-style="western"><surname>Ulloa</surname><given-names>R</given-names></name><name name-style="western"><surname>Kim</surname><given-names>C</given-names></name><name name-style="western"><surname>Fong</surname><given-names>M</given-names></name><name name-style="western"><surname>Xepoleas</surname><given-names>M</given-names></name><name name-style="western"><surname>Sinha</surname><given-names>U</given-names></name><name name-style="western"><surname>Kokot</surname><given-names>N</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>MS</given-names></name></person-group><article-title>Opioid sparing multimodal analgesia for transoral robotic surgery: improved analgesia and narcotic use reduction</article-title><source>OTO Open</source><year>2023</year><volume>7</volume><issue>1</issue><fpage>e17</fpage><pub-id pub-id-type="doi">10.1002/oto2.17</pub-id><pub-id pub-id-type="pmid">36998552</pub-id><pub-id pub-id-type="pmcid">PMC10046737</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Castellanos CX, Paoletti M, Ulloa R, Kim C, Fong M, Xepoleas M, Sinha U, Kokot N, Swanson MS (2023) Opioid sparing multimodal analgesia for transoral robotic surgery: improved analgesia and narcotic use reduction. OTO Open 7(1):e17. 10.1002/oto2.17. (<bold>PMID: 36998552; PMCID: PMC10046737</bold>)<pub-id pub-id-type="pmid">36998552</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/oto2.17</pub-id><pub-id pub-id-type="pmcid">PMC10046737</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ganti</surname><given-names>A</given-names></name><name name-style="western"><surname>Eggerstedt</surname><given-names>M</given-names></name><name name-style="western"><surname>Grudzinski</surname><given-names>K</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>EA</given-names></name><name name-style="western"><surname>Vaughan</surname><given-names>D</given-names></name><name name-style="western"><surname>Revenaugh</surname><given-names>PC</given-names></name><name name-style="western"><surname>Stenson</surname><given-names>K</given-names></name><name name-style="western"><surname>Al-Khudari</surname><given-names>S</given-names></name></person-group><article-title>Enhanced recovery protocol for transoral robotic surgery demonstrates improved analgesia and narcotic use reduction</article-title><source>Am J Otolaryngol</source><year>2020</year><volume>41</volume><issue>6</issue><fpage>102649</fpage><pub-id pub-id-type="doi">10.1016/j.amjoto.2020.102649</pub-id><pub-id pub-id-type="pmid">32717682</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Ganti A, Eggerstedt M, Grudzinski K, Ramirez EA, Vaughan D, Revenaugh PC, Stenson K, Al-Khudari S (2020) Enhanced recovery protocol for transoral robotic surgery demonstrates improved analgesia and narcotic use reduction. Am J Otolaryngol 41(6):102649. 10.1016/j.amjoto.2020.102649. (<bold>PMID: 32717682</bold>)<pub-id pub-id-type="pmid">32717682</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amjoto.2020.102649</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corso</surname><given-names>RM</given-names></name><name name-style="western"><surname>Gregoretti</surname><given-names>C</given-names></name><name name-style="western"><surname>Braghiroli</surname><given-names>A</given-names></name><name name-style="western"><surname>Fanfulla</surname><given-names>F</given-names></name><name name-style="western"><surname>Insalaco</surname><given-names>G</given-names></name></person-group><article-title>Practice guidelines for the perioperative management of patients with obstructive sleep apnea: navigating through uncertainty</article-title><source>Anesthesiology</source><year>2014</year><volume>121</volume><issue>3</issue><fpage>664</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1097/ALN.0000000000000354</pub-id><pub-id pub-id-type="pmid">25222681</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Corso RM, Gregoretti C, Braghiroli A, Fanfulla F, Insalaco G (2014) Practice guidelines for the perioperative management of patients with obstructive sleep apnea: navigating through uncertainty. Anesthesiology 121(3):664&#8211;665. 10.1097/ALN.0000000000000354. (<bold>PMID: 25222681</bold>)<pub-id pub-id-type="pmid">25222681</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/ALN.0000000000000354</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anne</surname><given-names>S</given-names></name><name name-style="western"><surname>Mims</surname><given-names>JW</given-names></name><name name-style="western"><surname>Tunkel</surname><given-names>DE</given-names></name><name name-style="western"><surname>Rosenfeld</surname><given-names>RM</given-names></name><name name-style="western"><surname>Boisoneau</surname><given-names>DS</given-names></name><name name-style="western"><surname>Brenner</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Clinical practice guideline: opioid prescribing for analgesia after common otolaryngology operations</article-title><source>Otolaryngol Head Neck Surg</source><year>2021</year><volume>164</volume><issue>2_suppl</issue><fpage>S1</fpage><lpage>S42</lpage><pub-id pub-id-type="doi">10.1177/0194599821996297</pub-id><pub-id pub-id-type="pmid">33822668</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Anne S, Mims JW, Tunkel DE, Rosenfeld RM, Boisoneau DS, Brenner MJ et al (2021) Clinical practice guideline: opioid prescribing for analgesia after common otolaryngology operations. Otolaryngol Head Neck Surg 164(2_suppl):S1&#8211;S42. 10.1177/0194599821996297. (<bold>PMID: 33822668</bold>)<pub-id pub-id-type="pmid">33822668</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0194599821996297</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cuschieri</surname><given-names>S</given-names></name></person-group><article-title>The STROBE guidelines</article-title><source>Saudi J Anaesth</source><year>2019</year><volume>13</volume><issue>Suppl.S1</issue><fpage>S31</fpage><lpage>S34</lpage><pub-id pub-id-type="doi">10.4103/sja.SJA_543_18</pub-id><pub-id pub-id-type="pmid">30930717</pub-id><pub-id pub-id-type="pmcid">PMC6398292</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Cuschieri S (2019) The STROBE guidelines. Saudi J Anaesth 13(Suppl.S1):S31&#8211;S34. 10.4103/sja.SJA_543_18. (<bold>PMID: 30930717; PMCID: PMC6398292</bold>)<pub-id pub-id-type="pmid">30930717</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/sja.SJA_543_18</pub-id><pub-id pub-id-type="pmcid">PMC6398292</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">European Society of Anaesthesiology and Intensive Care. The ENCORE Study. Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://esaic.org/study/the-encore-study/">https://esaic.org/study/the-encore-study/</ext-link> (Accessed on 5 Jan 2025).</mixed-citation></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsieh</surname><given-names>CY</given-names></name><name name-style="western"><surname>Sun</surname><given-names>CH</given-names></name><name name-style="western"><surname>Lin</surname><given-names>CC</given-names></name><name name-style="western"><surname>Chou</surname><given-names>YF</given-names></name></person-group><article-title>Comparative analysis of ketorolac and parecoxib for postoperative pain management in uvulopalatopharyngoplasty</article-title><source>J Clin Med</source><year>2024</year><volume>13</volume><fpage>4422</fpage><pub-id pub-id-type="doi">10.3390/jcm13154422</pub-id><pub-id pub-id-type="pmid">39124688</pub-id><pub-id pub-id-type="pmcid">PMC11312481</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Hsieh CY, Sun CH, Lin CC, Chou YF (2024) Comparative analysis of ketorolac and parecoxib for postoperative pain management in uvulopalatopharyngoplasty. J Clin Med 13:4422. 10.3390/jcm13154422. (<bold>PMID: 39124688; PMCID: PMC11312481</bold>)<pub-id pub-id-type="pmid">39124688</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm13154422</pub-id><pub-id pub-id-type="pmcid">PMC11312481</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>GL</given-names></name><name name-style="western"><surname>Chu</surname><given-names>QJ</given-names></name><name name-style="western"><surname>Liu</surname><given-names>CL</given-names></name></person-group><article-title>Application of parecoxib in post-uvulopalatopharyngoplasty analgesia</article-title><source>J Int Med Res</source><year>2013</year><volume>41</volume><fpage>1699</fpage><lpage>1704</lpage><pub-id pub-id-type="doi">10.1177/0300060513489473</pub-id><pub-id pub-id-type="pmid">23934045</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Xie GL, Chu QJ, Liu CL (2013) Application of parecoxib in post-uvulopalatopharyngoplasty analgesia. J Int Med Res 41:1699&#8211;1704. 10.1177/0300060513489473. (<bold>PMID: 23934045</bold>)<pub-id pub-id-type="pmid">23934045</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0300060513489473</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kendale</surname><given-names>SM</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Blitz</surname><given-names>JD</given-names></name><name name-style="western"><surname>Calvino</surname><given-names>S</given-names></name><name name-style="western"><surname>Cuff</surname><given-names>G</given-names></name><name name-style="western"><surname>Barone</surname><given-names>N</given-names></name><name name-style="western"><surname>Rosenberg</surname><given-names>AD</given-names></name><name name-style="western"><surname>Doan</surname><given-names>L</given-names></name></person-group><article-title>A retrospective study of opioid prescribing patterns at hospital discharge in surgical patients with obstructive sleep apnea</article-title><source>Can J Anaesth</source><year>2018</year><volume>65</volume><fpage>914</fpage><lpage>922</lpage><pub-id pub-id-type="doi">10.1007/s12630-018-1152-9</pub-id><pub-id pub-id-type="pmid">29777388</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Kendale SM, Wang J, Blitz JD, Calvino S, Cuff G, Barone N, Rosenberg AD, Doan L (2018) A retrospective study of opioid prescribing patterns at hospital discharge in surgical patients with obstructive sleep apnea. Can J Anaesth 65:914&#8211;922. 10.1007/s12630-018-1152-9. (<bold>PMID: 29777388</bold>)<pub-id pub-id-type="pmid">29777388</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12630-018-1152-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saroya</surname><given-names>J</given-names></name><name name-style="western"><surname>Singh</surname><given-names>A</given-names></name><name name-style="western"><surname>Chang</surname><given-names>JL</given-names></name><name name-style="western"><surname>Durr</surname><given-names>ML</given-names></name></person-group><article-title>Opioid prescription trends among sleep surgeons in the United States</article-title><source>Laryngoscope</source><year>2024</year><volume>134</volume><fpage>4810</fpage><lpage>4817</lpage><pub-id pub-id-type="doi">10.1002/lary.31543</pub-id><pub-id pub-id-type="pmid">38877817</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Saroya J, Singh A, Chang JL, Durr ML (2024) Opioid prescription trends among sleep surgeons in the United States. Laryngoscope 134:4810&#8211;4817. 10.1002/lary.31543. (<bold>PMID: 38877817</bold>)<pub-id pub-id-type="pmid">38877817</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/lary.31543</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baugh</surname><given-names>R</given-names></name><name name-style="western"><surname>Burke</surname><given-names>B</given-names></name><name name-style="western"><surname>Fink</surname><given-names>B</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>R</given-names></name><name name-style="western"><surname>Kominsky</surname><given-names>A</given-names></name><name name-style="western"><surname>Yaremchuk</surname><given-names>K</given-names></name></person-group><article-title>Safety of outpatient surgery for obstructive sleep apnea</article-title><source>Otolaryngol Head Neck Surg</source><year>2013</year><volume>148</volume><fpage>867</fpage><lpage>872</lpage><pub-id pub-id-type="doi">10.1177/0194599813479776</pub-id><pub-id pub-id-type="pmid">23449781</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Baugh R, Burke B, Fink B, Garcia R, Kominsky A, Yaremchuk K (2013) Safety of outpatient surgery for obstructive sleep apnea. Otolaryngol Head Neck Surg 148:867&#8211;872. 10.1177/0194599813479776. (<bold>PMID: 23449781</bold>)<pub-id pub-id-type="pmid">23449781</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0194599813479776</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patroc&#237;nio</surname><given-names>LG</given-names></name><name name-style="western"><surname>Rangel</surname><given-names>MDO</given-names></name><name name-style="western"><surname>Miziara</surname><given-names>GSM</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>AM</given-names></name><name name-style="western"><surname>Patroc&#237;nio</surname><given-names>JA</given-names></name><name name-style="western"><surname>Patrocinio</surname><given-names>TG</given-names></name></person-group><article-title>A comparative study between ketorolac and ketoprofen in postoperative pain after uvulopalatopharyngoplasty</article-title><source>Braz J Otorhinolaryngol</source><year>2007</year><volume>73</volume><fpage>339</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1016/s1808-8694(15)30077-x</pub-id><pub-id pub-id-type="pmid">17684654</pub-id><pub-id pub-id-type="pmcid">PMC9445687</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Patroc&#237;nio LG, Rangel MDO, Miziara GSM, Rodrigues AM, Patroc&#237;nio JA, Patrocinio TG (2007) A comparative study between ketorolac and ketoprofen in postoperative pain after uvulopalatopharyngoplasty. Braz J Otorhinolaryngol 73:339&#8211;342. 10.1016/s1808-8694(15)30077-x. (<bold>PMID:17684654;PMCID:PMC9445687</bold>)<pub-id pub-id-type="pmid">17684654</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1808-8694(15)30077-X</pub-id><pub-id pub-id-type="pmcid">PMC9445687</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Badash</surname><given-names>I</given-names></name><name name-style="western"><surname>Wong</surname><given-names>S</given-names></name><name name-style="western"><surname>Biju</surname><given-names>K</given-names></name><name name-style="western"><surname>Hur</surname><given-names>K</given-names></name><name name-style="western"><surname>Commesso</surname><given-names>E</given-names></name><name name-style="western"><surname>Kezirian</surname><given-names>EJ</given-names></name></person-group><article-title>Association between perioperative celecoxib, acetaminophen, and opioid consumption after palate surgery for obstructive sleep apnea</article-title><source>Otolaryngol Head Neck Surg</source><year>2024</year><volume>172</volume><fpage>678</fpage><lpage>685</lpage><pub-id pub-id-type="doi">10.1002/ohn.1069</pub-id><pub-id pub-id-type="pmid">39588650</pub-id><pub-id pub-id-type="pmcid">PMC12139123</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Badash I, Wong S, Biju K, Hur K, Commesso E, Kezirian EJ (2024) Association between perioperative celecoxib, acetaminophen, and opioid consumption after palate surgery for obstructive sleep apnea. Otolaryngol Head Neck Surg 172:678&#8211;685. 10.1002/ohn.1069. (<bold>PMID: 39588650</bold>)<pub-id pub-id-type="pmid">39588650</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ohn.1069</pub-id><pub-id pub-id-type="pmcid">PMC12139123</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yeh</surname><given-names>CY</given-names></name><name name-style="western"><surname>Jao</surname><given-names>SW</given-names></name><name name-style="western"><surname>Chen</surname><given-names>JS</given-names></name><name name-style="western"><surname>Fan</surname><given-names>CW</given-names></name><name name-style="western"><surname>Chen</surname><given-names>HH</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>PS</given-names></name><name name-style="western"><surname>Wu</surname><given-names>CC</given-names></name><name name-style="western"><surname>Lee</surname><given-names>CC</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>YH</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Sebacoyl dinalbuphine ester extended-release injection for long-acting analgesia: a multicenter, randomized, double-blind, and placebo-controlled study in hemorrhoidectomy patients</article-title><source>Clin J Pain</source><year>2017</year><volume>33</volume><fpage>429</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1097/AJP.0000000000000417</pub-id><pub-id pub-id-type="pmid">27518486</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Yeh CY, Jao SW, Chen JS, Fan CW, Chen HH, Hsieh PS, Wu CC, Lee CC, Kuo YH, Hsieh MC et al (2017) Sebacoyl dinalbuphine ester extended-release injection for long-acting analgesia: a multicenter, randomized, double-blind, and placebo-controlled study in hemorrhoidectomy patients. Clin J Pain 33:429&#8211;434. 10.1097/AJP.0000000000000417. (<bold>PMID: 27518486</bold>)<pub-id pub-id-type="pmid">27518486</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/AJP.0000000000000417</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>YE</given-names></name><name name-style="western"><surname>Wang</surname><given-names>SY</given-names></name><name name-style="western"><surname>Chen</surname><given-names>JH</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CY</given-names></name><name name-style="western"><surname>Shiue</surname><given-names>YL</given-names></name><name name-style="western"><surname>Soong</surname><given-names>TC</given-names></name><name name-style="western"><surname>Lam</surname><given-names>CF</given-names></name></person-group><article-title>Efficacy and safety of parenteral injection of an extended release &#954;-receptor opioid sebacoyl dinalbuphine ester for acute and chronic pain after laparoscopic bariatric surgery: a randomized, placebo-controlled, double-blind trial</article-title><source>Obes Surg</source><year>2023</year><volume>33</volume><fpage>1192</fpage><lpage>1201</lpage><pub-id pub-id-type="doi">10.1007/s11695-023-06502-9</pub-id><pub-id pub-id-type="pmid">36787017</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Lee YE, Wang SY, Chen JH, Chen CY, Shiue YL, Soong TC, Lam CF (2023) Efficacy and safety of parenteral injection of an extended release &#954;-receptor opioid sebacoyl dinalbuphine ester for acute and chronic pain after laparoscopic bariatric surgery: a randomized, placebo-controlled, double-blind trial. Obes Surg 33:1192&#8211;1201. 10.1007/s11695-023-06502-9. (<bold>PMID: 36787017</bold>)<pub-id pub-id-type="pmid">36787017</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11695-023-06502-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Memtsoudis</surname><given-names>SG</given-names></name><name name-style="western"><surname>Cozowicz</surname><given-names>C</given-names></name><name name-style="western"><surname>Nagappa</surname><given-names>M</given-names></name><name name-style="western"><surname>Wong</surname><given-names>J</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>GP</given-names></name><name name-style="western"><surname>Wong</surname><given-names>DT</given-names></name><etal/></person-group><article-title>Society of anesthesia and sleep medicine guideline on intraoperative management of adult patients with obstructive sleep apnea</article-title><source>Anesth Analg</source><year>2018</year><volume>127</volume><issue>4</issue><fpage>967</fpage><lpage>987</lpage><pub-id pub-id-type="doi">10.1213/ANE.0000000000003434</pub-id><pub-id pub-id-type="pmid">29944522</pub-id><pub-id pub-id-type="pmcid">PMC6135479</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Memtsoudis SG, Cozowicz C, Nagappa M, Wong J, Joshi GP, Wong DT et al (2018) Society of anesthesia and sleep medicine guideline on intraoperative management of adult patients with obstructive sleep apnea. Anesth Analg 127(4):967&#8211;987. 10.1213/ANE.0000000000003434. (<bold>PMID: 29944522; PMCID: PMC6135479</bold>)<pub-id pub-id-type="pmid">29944522</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1213/ANE.0000000000003434</pub-id><pub-id pub-id-type="pmcid">PMC6135479</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>